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Background. In Sudan, tuberculosis diagnosis largely relies on clinical symptoms and smear microscopy as in many other low-
and middle-income countries. The aim of this study was to investigate the positive predictive value of a positive sputum smear in
patients investigated for pulmonary tuberculosis in Eastern Sudan. Methods. Two sputum samples from patients presenting with
symptoms suggestive of tuberculosiswere investigated using direct Ziehl-Neelsen (ZN) staining and lightmicroscopy between June
to October 2014 and January to July 2016. If one of the samples was smear positive, both samples were pooled, stored at −20∘C, and
sent to the National Reference Laboratory (NRL), Germany. Following decontamination, samples underwent repeat microscopy
and culture. Culture negative/contaminated samples were investigated using polymerase chain reaction (PCR). Results. A total of
383 samples were investigated. Repeat microscopy categorized 123 (32.1%) as negative, among which 31 were culture positive. This
increased to 80 when PCR and culture results were considered together. A total of 196 samples were culture positive, of which 171
(87.3%), 14 (7.1%), and 11 (5.6%)wereM. tuberculosis,M. intracellulare, andmixed species. Overall, 15.6% (57/365) of the samples had
no evidence ofM. tuberculosis, resulting in a positive predictive value of 84.4%. Conclusions. There was a discordance between the
results of smear microscopy performed at local laboratories in the Sudan and at the NRL, Germany; besides, a considerable number
of samples had no evidence of M. tuberculosis. Improved quality control for smear microscopy and more specific diagnostics are
crucial to avoid possible overtreatment.
1. Background
Worldwide, an estimated 10.4 million new tuberculosis cases
occurred in 2016 with the majority of cases originating
from low- and middle-income countries [1]. More than
a third of these cases remained undiagnosed. Rapid and
accurate diagnosis of tuberculosis is critical for timely ini-
tiation of treatment and, ultimately, control of the disease.
Xpert MTB/Rif, a molecular test designed for testing clinical
specimens in low-level laboratories and primary health care
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Figure 1: Map of the Sudan showing the three sampling sites. The capital city of the Sudan, Khartoum, is indicated by a blue circle and the
three sampling sites are indicated by different red shapes. El-Gadarif is indicated by a square, Kassala is indicated by a star, and Port Sudan is
indicated by a triangle.
clinics, has changed the diagnostic landscape [2, 3]. Xpert
MTB/Rif has become an integral part of tuberculosis diagnos-
tic algorithms inmany low- andmiddle-income countries [3–
5]. However, despite the successful roll-out of XpertMTB/Rif,
smear microscopy remains the primary diagnostic tool for
tuberculosis in most low-resource settings.
Sensitivity and specificity of smear microscopy for diag-
nosis of tuberculosis have been reported to be 30–89%
and 93–100% in the context of passive tuberculosis case
finding [6, 7]. Lower specificities have been reported in the
context of tuberculosis prevalence surveys [8]. Some of the
root causes of false positive smear microscopy results are
laboratory errors such as analytic errors or sample mix-
ups and the inability of smear microscopy to differentiate
between Mycobacterium tuberculosis complex (MTBC) and
nontuberculous mycobacteria (NTM). In many low- and
middle-income countries, considerable efforts have been
made to implement external quality assurance schemes for
smear microscopy to address analytic errors [9]. Sudan,
more specifically Eastern Sudan, has an external quality
assurance scheme. The EQA scheme rechecks a number of
randomly selected slides on a regular basis [10]. The inability
of smear microscopy to differentiate between MTBC and
NTM infections is further complicated by the fact that clini-
cally and radiologically respiratory NTM infections resemble
pulmonary tuberculosis. Therefore, the specificity of smear
microscopy for diagnosing tuberculosis is influenced by both
diagnostic quality and prevalence of NTM infections, with
important implications for clinical decision-making.
In Sudan, tuberculosis diagnosis largely relies on clinical
symptoms and smear microscopy as in many other low- and
middle-income countries [11, 12]. More advanced diagnostics
such as Xpert MTB/Rif or polymerase chain reaction (PCR)
and culture are not available for routine tuberculosis diagno-
sis at the present time. This study aimed at investigating the
positive predictive value (PPV) of Ziehl-Neelsen (ZN) smear
microscopy in Eastern Sudan which is influenced by both
diagnostic specificity and prevalence of the disease.
2. Materials and Methods
2.1. Study Setting. This study was conducted in three sites in
Eastern Sudan, namely, Kassala, Port Sudan, and El-Gadarif
(Figure 1). Eastern Sudan shares international borders with
Ethiopia, Eritrea, and Egypt and national borders with five
states in the Sudan. The three selected sampling sites serve
as referral clinics for tuberculosis and respiratory diseases
and are very close to international borders. Approximately
600,000 people live in the catchment area of the three clinics.
These people are mainly Beja, Arabs, Nubians, West Africans,
and small minorities of Asians and Europeans. Between 700
and 1300 tuberculosis cases are registered every year in each
of the three surveyed hospitals. Smear positivity is around
40%–50% [13–15]. Generally, HIV prevalence in Eastern
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Sudan was documented to be up to 0.5% while it is as high as
18.3% among tuberculosis patients [15, 16]. Overall, only 17%
of all registered TB cases in the Sudan have knownHIV status
[1]. Eastern Sudan has witnessed an armed conflict for a long
time. It ended in 2006 after signing of the peace agreement
between the government and the rebel groups.
2.2. Study Population and Sampling. A total of 383 sputum
samples of participants diagnosed with pulmonary tubercu-
losis on the basis of smear microscopy, clinical presentation,
and chest radiography were included in this study. Patients
were recruited from the outpatient department at Kassala,
Port Sudan, and El-Gadarif teaching hospitals in Eastern
Sudan over two recruitment periods: from June to October
2014 and from January to July 2016. Two sputum samples,
a spot and an early morning, were collected from each
patient. These sputum samples were subjected to direct ZN
microscopy at the site of collection [6]. If at least one of
the samples was smear positive, the two sputum samples
were pooled, stored at −20∘C, and shipped in two separate
batches to the National Reference Laboratory (NRL), Borstel,
Germany. The maximum period of samples storage was 6
months. All samples collected during one recruitment period
were shipped together. The transit period from the Sudan to
Germany was 3 days for the first batch of samples and it was
longer for the second batch. All samples were shipped at room
temperature.
2.3. Laboratory Procedures at the NRL, Germany. Samples
were processed according to current guidelines by decon-
tamination and digestion with sodium hydroxide/N-acetyl
cysteine (NALC-NaOH) [17]. A portion of the resuspended
sputum pellet was used for smear microscopy. Samples
collected in 2014 (𝑛 = 101) were stained using the Kinyoun
method in conjunction with an automated staining system
(ZN Aerospray TB Slide Stainer/Cytocentrifuge, Wescor,
Logan, USA) and read using light microscopy (oil immersion
lens, 100x). Samples collected in 2016 (𝑛 = 282) were
stained using auramineO staining and readwith a fluorescent
light-emitting diode (LED) microscope (40x). Results were
recorded as smear positive or smear negative. All smear
positive samples were graded as scanty (+/−), 1+, 2+, and 3+,
according to theWorld Health Organization (WHO) grading
system.
The decontaminated samples were aseptically inoculated
into mycobacterial growth indicator tubes (MGIT; Becton-
Dickinson, Heidelberg, Germany) primed with growth sup-
plement and antibiotics (PANTA; Becton-Dickinson, Hei-
delberg, Germany). The MGIT were incubated in the BD
MGIT960 instrument for amaximumof 42 days. In addition,
culture on Lo¨wenstein-Jensen and Stonebrink slopes (own
production or Enclit, Leipzig, Germany) with antibiotic
supplement was performed and incubated at 37∘C for a
maximum of 56 days.
Positive cultures were examinedmicroscopically for acid-
fast bacilli using Kinyoun stain and inoculated on Columbia
blood agar (Becton-Dickinson, Heidelberg, Germany) to rule
out contamination. Identification of the grown mycobacteria
was done using a commercially available line probe assay
(HAIN GenoType CM and GenoType TBC; HAIN Life-
science GmbH, Nehren, Germany) and the internal tran-
scribed spacer (ITS) sequencing. Flag-positive MGIT that
demonstrated the presence of contaminants on staining and
blood agar were subcultured on Lo¨wenstein-Jensen slopes
with antibiotic supplement and incubated for another 28
days at 37∘C. Culture results were reported as positive for
mycobacteria if there was growth on at least one of the three
cultures or the subculture or negative if no growth occurred
in any of the liquid and solid media, and contaminated if all
three cultures and the subculture were contaminated.
Sediments which did not reveal any positive result for
mycobacteria on culture in 2016 were tested using an in-
house real-time PCR detecting MTBC or NTM as previ-
ously described [18]. For this, deoxyribonucleic acid (DNA)
extraction was performed on the stored sputum pellets
using QIAamp DNA Minikit (QIAGEN GmbH, Hilden,
Germany) as per the manufacturer’s instructions.
2.4. Analysis. Data were entered into an Excel database. Pro-
portions and 95% confidence intervals (CI) were calculated
using the Statistical Package for the Social Sciences (SPSS)
(version 20.0, SPSS Inc., Chicago, Illinois). Chi square tests
were used to compare proportions.
3. Results
A total of 383 samples were included in the analysis: 161
(42%), 133 (34.7%), and 89 (23.2%) from El-Gadarif, Kassala,
and Port Sudan, respectively (Figure 2). The median age
of the patients was 35 (interquartile range 25; 45). A small
proportion of patients were under 15 years of age (𝑛 = 13,
3.4%); the majority were men (𝑛 = 245, 64%).
Smear scores determined in Sudan and at the NRL,
Germany, were different (Figure 2). In total, one-third of the
sample (𝑛 = 123, 32.1%) tested smear positive in Sudan
were categorized as smear negative at the NRL in Germany
(Table 1). Of those samples, 89 (72.4%), 22 (17.9%), and 7
(5.7%) were scored 1+, 2+, and 3+, respectively, in Sudan,
while smear scores of 5 (4.0%) samples were missing.
A total of 196 (51.2%) samples revealed mycobacterial
growth, while 136 (35.5%) did not show any growth and 51
(13.3%)were contaminated (Figure 2).Themajority (𝑛 = 171,
87.3%) of mycobacterial isolates were identified as M. tuber-
culosis, 14 (7.1%) isolates were identified as M. intracellulare
group, and 11 (5.6%) cultures were mixed, of which seven
were amixture ofM. tuberculosis andM. intracellulare group,
oneM. tuberculosis andM. fortuitum, oneM. tuberculosis and
M. asiaticum, and one M. tuberculosis and Corynebacterium
species, and one was a mixture ofM. intracellulare group and
an unknown Mycobacterium species. A total of 187 (48.8%)
samples were culture negative or contaminated, of which 169
were subjected to real-time PCR and 127/169 (75.1%) tested
positive for MTBC DNA and 8/169 (4.7%) for NTM DNA.
Among those samples with negative smear microscopy
results (𝑛 = 123; 32.1%) at the NRL in Germany, 31
(25.2%) were culture positive growing MTBC. The detec-
tion rate increased to 80 (71%) samples when PCR and
culture results were taken together into account (Table 1).
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Individuals presenting with symptoms 
suggestive of tuberculosis
89 samples from 
Port Sudan
133 samples 
from Kassala
161 samples 
from El-Gadarif
Decontamination and digestion by 
NALC-NaOH method 
(383 samples)
Samples collected in 2014 (n = 101) 
subjected to Kinyoun stain
Samples collected in 2016 
(n = 282) subjected to auramine O
190 positive92 negative70 positive 31 negative
Culturing into MGIT and
onto slants (383 samples)
136 negative 196 positive51 contaminated
18 no PCR 169 tested by PCR and ITS sequencing 196 tested by HAIN and ITS sequencing
14 NTM 171 MTBC127 MTBC 11 Mix8 NTM
34 samples with no
evidence of presence of
mycobacteria (negative)
331 samples with evidence
of presence of
mycobacteria (positive)
Figure 2: Flowchart of the results. NALC-NaOH: sodium hydroxide/N-acetyl cysteine; MGIT: mycobacteria growth indicator tube; PCR:
polymerase chain reaction; HAIN: line probe assay for GenoType CM and GenoType MTBC; MTBC:Mycobacterium tuberculosis complex;
NTM: nontuberculousmycobacteria; Mix: two different mycobacteria grown on the same culture.
A total of 34 culture negative samples tested by PCR did
not show any evidence of mycobacterial DNA, in addition
to 23 samples that had only evidence of NTM by culture
or PCR. Overall, 57 (15.6%) samples had no evidence of
MTBC either by culture or by PCR, compared to 308
samples for which either by culture or PCR MTBC could
be proven, resulting in a positive predictive value of smear
microscopy for tuberculosis of 84.4% (95% CI: 80.7–88.1)
(Table 1 and Figure 2).
4. Discussion
This study revealed that 10% of samples categorized as
smear positive in the Sudan did not have any evidence of
mycobacteria using culture or PCR as reference standard in
Germany. Concordance of smear scores determined by local
microscopy centers in Sudan and at the NRL in Germany was
suboptimal. A third of samples categorized as smear positive
in Sudan were found to be negative at the NRL in Germany.
Tuberculosis Research and Treatment 5
Ta
bl
e
1:
M
yc
ob
ac
te
ria
lc
ul
tu
re
an
d
PC
R
re
su
lts
str
at
ifi
ed
by
sm
ea
rs
co
re
s.
N
RL
sm
ea
r
sc
or
e
To
ta
l
Cu
ltu
re
po
sit
iv
ef
or
m
yc
ob
ac
te
ria
To
ta
l
PC
R
po
sit
iv
ef
or
m
yc
ob
ac
te
ria
To
ta
l
Cu
ltu
re
or
PC
R
po
sit
iv
ef
or
m
yc
ob
ac
te
ria
To
ta
l
Cu
ltu
re
or
PC
R
po
sit
iv
ef
or
M
TB
C
N
um
be
r
%
(9
5%
CI
)
N
um
be
r
%
(9
5%
CI
)
N
um
be
r
%
(9
5%
CI
)
N
um
be
r
%
(9
5%
CI
)
N
eg
at
iv
e
12
3
31
25
.2
(1
7.5
–3
2.
9)
82
49
59
.8
(4
8.
8–
70
.8
)
113
80
71
.0
(6
3.
4–
79
.4
)
113
70
62
.0
(5
3.
0–
71
.0
)
Sc
an
ty
110
68
62
.0
(5
2.
9–
71
.1)
38
37
97
.4
(9
5.
8–
99
.8
)
10
6
10
5
99
.1
(9
8.
3–
99
.9
)
10
6
98
92
.5
(8
7.5
–9
7.5
)
1+
77
43
55
.8
(4
4.
8–
66
.8
)
34
34
10
0
(0
.0
0-
0.
00
)
77
77
10
0
(0
.0
0-
0.
00
)
77
74
96
.0
(9
2.
0–
10
0)
2+
49
34
69
.4
(5
6.
4–
82
.4
)
12
12
10
0
(0
.0
0-
0.
00
)
46
46
10
0
(0
.0
0-
0.
00
)
46
44
96
.0
(9
3.
2–
99
.2
)
3+
24
20
83
.3
(6
8.
3–
98
.3
)
3
3
10
0
(0
.0
0-
0.
00
)
23
23
10
0
(0
.0
0-
0.
00
)
23
22
96
.0
(9
3.
8–
99
.8
)
To
ta
l
38
3
19
6
51
.2
(4
6.
2–
56
.2
)
16
9
13
5
80
.0
(7
4.
0–
86
.0
)
36
5
33
1
91
.0
(8
7.4
–9
5.
4)
36
5
30
8
84
.7
(8
0.
7–
88
.1)
N
RL
:N
at
io
na
lR
ef
er
en
ce
La
bo
ra
to
ry
.
6 Tuberculosis Research and Treatment
Table 2: Expected positive predictive values of smear microscopy
assuming a sensitivity of 55% in the context of passive case finding.
Positive predictive
value
Proportion with
smear positive TB Specificity
75.3% 10% 98%
83.0% 15% 98%
87.3% 20% 98%
90.2% 25% 98%
86.0% 10% 99%
91.0% 15% 99%
93.2% 20% 99%
95.0% 25% 99%
In most resource-limited settings, tuberculosis is diag-
nosed on the basis of smear microscopy and clinical findings.
In the context of passive case finding, smear positivity is
usually 10%–15%. Assuming a specificity of 98-99% and
smear positivity rate of 10%–15%, positive predictive values
in the range of 75%–91% would be expected (Table 2) [19].
Positive predictive values reported by African and Asian
investigators vary considerably (60–98%) [20–26]. The het-
erogeneity of results might be explained by differences in
tuberculosis prevalence and smear specificity. Unfortunately,
neither prevalence nor specificity was assessed in this study,
precluding any firm conclusions regarding the underlying
cause of the low positive predictive value.
Generally, suboptimal smear specificity for tuberculosis
is due to two reasons: (i) faulty microscopy and (ii) presence
of NTMs. In this study, decreased specificity was equally
attributable to reading and staining errors and the presence of
NTMs. All but one of the culture and PCR negative samples
(𝑛 = 33) were smear negative on repeat examination at the
NRL. Reading and staining errors are best addressed through
adequate training, regular supervision, and national external
quality assurance schemes [6, 9]. Differentiation between M.
tuberculosis and NTMs requires molecular diagnostics such
as Xpert MTB/Rif or culture.
In this study, one of seven patients diagnosed with smear
positive pulmonary tuberculosis at local hospitals did not
have any evidence of M. tuberculosis bacilli in their sputum
samples by culture or PCR performed in Germany. These
patients were initiated on quadruple therapy with potentially
toxic drugs but might not have had tuberculosis. At best, if
those patients really did not have tuberculosis, theywould not
have benefited from treatment but would have stayed alive
with untreated chronic lung disease such as bronchiectasis.
At worst, those individuals would have deteriorated and/or
died from their underlying disease such as lung cancer,
chronic obstructive lung disease, fibrosis, or other diseases
such as NTM infection. However, in low-resource settings
with limited diagnostics and treatment options, there is little
one can offer patients with potentially fatal lung disease with
the exception of acute pneumonia and tuberculosis. This
needs to be weighed against the fact that individuals receiving
treatment for tuberculosis and their families will experience
significant costs associated with treatment. Costs are also
accrued by the health care system [27, 28].
This study has several strengths. It was a multisite study
conducted in three public hospitals in Eastern Sudan, making
the findings generalizable to similar settings. Cultures and
molecular diagnostics were performed in a national reference
laboratory in a high-resource setting. The combination of
molecular diagnostics together with one liquid and two solid
cultures reduced the likelihood of misclassifying a sample as
negative.
The limitations of the study include lack of data on
sensitivity and specificity of smear microscopy in this setting
and unknown tuberculosis prevalence among individuals
presenting for investigations. Furthermore, prolonged transit
time might have resulted in some samples being falsely
classified as culture negative. However, this was addressed
by investigating culture negative samples with molecular
methods. Clinical data such as HIV status, chest radiography
findings, and treatment outcomes were not available. Two
samples from each patient were pooled. If one of the samples
was smear negative and the other one scanty smear positive,
the pooled samples might be classified as smear negative at
the NRL.
In summary, there was a discordance between the results
of smear microscopy performed at local laboratories in the
Sudan and at the NRL, Germany. Additionally, the positive
predictive value of smear microscopy in Eastern Sudan
was less than 90%. Half of the false positive results were
due to reading and staining errors, while the other half
was due to the presence of NTMs. The former needs to
be addressed through quality assurance schemes, training,
and supervision; the latter would require a more specific
confirmatory test such as theXpertMTB/Rif, othermolecular
diagnostics, or culture to avoid possible overtreatment. This
is even more important in the context of active case finding
when pretest probability is lower compared to passive case
finding [29].
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